MAPT and Alzheimer disease: Similarly, a case-control study described how Tau PET shows a higher magnitude of binding in MAPT mutation carriers who harbor mutations that are more likely to produce an AD-like Tau pathology, supporting the notion that this Tau PET ligand has specific binding properties for an AD-like Tau pathology [71].